Amlodipin ve atorvastatin etkileşimleri

Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function. (Betaksolol etiketi, İlaç etkileşimleri)

The concomitant use of RYANODEX and calcium channel blockers is not recommended during the treatment of malignant hyperthermia. (Dantrolen etiketi, İlaç etkileşimleri)

Lipid Modifying Agents: HMG-CoA reductase inhibitors : lovastatin, simvastatin ↑ lovastatin ↑ simvastatin Co-administration is contraindicated due to potential for serious reactions such as myopathy including rhabdomyolysis. atorvastatin, pravastatin, rosuvastatin ↑ HMG-CoA reductase inhibitors Co-administration of PREZISTA/ritonavir with HMG-Co A reductase inhibitors… (Darunavir etiketi, İlaç etkileşimleri)

Dosage recommendations with atorvastatin or rosuvastatin are as follows: atorvastatin dosage should not exceed 20 mg/day rosuvastatin dosage should not exceed 20 mg/day Other lipid modifying agents: lomitapide ↑ lomitapide Co-administration is contraindicated due to potential for markedly increased transaminases associated with increased plasma concentrations… (Darunavir ve kobisistat etiketi, İlaç etkileşimleri)

• Statins: Avoid simvastatin doses greater than 10 mg daily. (Dronedaron etiketi, İlaç etkileşimleri)

Lipid-modifying Agents: HMG-CoA Reductase Inhibitors: lovastatin simvastatin ↑ lovastatin ↑ simvastatin Coadministration with lovastatin or simvastatin is contraindicated due to potential for serious reactions such as myopathy including rhabdomyolysis. atorvastatin ↑ atorvastatin Initiate atorvastatin with the lowest starting dose of atorvastatin and titrate… (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (Eptifibatid etiketi, Kontrendikasyonlar)

Do not use erythromycin concomitantly with HMG CoA reductase inhibitors (statins) that are extensively metabolized by CYP 3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see PRECAUTIONS - Drug Interactions ). (Eritromisin etiketi, Kontrendikasyonlar)

IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC and intravenous verapamil. (Esmolol etiketi, Kontrendikasyonlar)

When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (Ezetimib etiketi, Kontrendikasyonlar)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (Ferrik sitrat etiketi, İlaç etkileşimleri)

Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir or glecaprevir plus pibrentasvir with amlodipine and atorvastatin tablets are not recommended. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Concomitant intake of large quantities, more than 1.2 liters daily, of grapefruit juice is not recommended in patients taking amlodipine and atorvastatin tablets [see Drug Interactions (7.3) ]. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Calcium Channel Blockers Felodipine Nisoldipine Contraindicated during and 2 weeks after TOLSURA treatment. (İtrakonazol etiketi, İlaç etkileşimleri)

• Calcium Channel Blockers: Avoid concomitant use with Calcium Chloride Injection. (Kalsiyum klorür etiketi, İlaç etkileşimleri)

Myopathy Coadministration of CYP3A4 metabolized HMG-CoA reductase inhibitors such as simvastatin, and lovastatin is contraindicated with ketoconazole tablets (see PRECAUTIONS: Drug Interactions ). (Ketokonazol etiketi, Kontrendikasyonlar)

In situations where the concomitant use of clarithromycin tablets with atorvastatin or pravastatin cannot be avoided, atorvastatin dose should not exceed 20 mg daily and pravastatin dose should not exceed 40 mg daily. (Klaritromisin etiketi, Uyarılar ve önlemler)

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (Klozapin etiketi, Kutulu uyarı)

IV administration of non-dihydropyridine calcium-channel antagonists (e.g., verapamil) Hypersensitivity reactions, including anaphylaxis, to labetalol Bronchial asthma ( 4 ) (Labetalol etiketi, Kontrendikasyonlar)

Coadministration of ledipasvir and sofosbuvir with rosuvastatin is not recommended. atorvastatin ↑ atorvastatin Coadministration of ledipasvir and sofosbuvir with atorvastatin may be associated with increased risk of myopathy, including rhabdomyolysis. (Ledipasvir ve sofosbuvir etiketi, İlaç etkileşimleri)

Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir or glecaprevir plus pibrentasvir with amlodipine and atorvastatin tablets are not recommended. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (Metolazon etiketi, Uyarılar)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Minoksidil etiketi, Kutulu uyarı)

Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir or glecaprevir plus pibrentasvir with amlodipine and atorvastatin tablets are not recommended. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Prevention or Management Atorvastatin, Lovastatin, Simvastatin Concomitant use with posaconazole is contraindicated. (Posakonazol etiketi, İlaç etkileşimleri)

Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir or glecaprevir plus pibrentasvir with amlodipine and atorvastatin tablets are not recommended. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir or glecaprevir plus pibrentasvir with amlodipine and atorvastatin tablets are not recommended. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

…↑ pitavastatin Coadministration with VOSEVI may increase the concentration of pitavastatin and is not recommended, due to an increased risk of myopathy, including rhabdomyolysis. atorvastatin fluvastatin lovastatin simvastatin ↑ atorvastatin ↑ fluvastatin ↑ lovastatin ↑ simvastatin Coadministration with VOSEVI may increase the concentrations of atorvastatin,… (Sofosbuvir ve velpatasvir etiketi, İlaç etkileşimleri)

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (Tadalafil etiketi, Uyarılar ve önlemler)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (Adrenalin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (Alfuzosin etiketi, Uyarılar ve önlemler)

Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [see Use in Specific Populations (8.7) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher amlodipine and atorvastatin dosage. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

• Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher amlodipine and atorvastatin dosage. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

• Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher amlodipine and atorvastatin dosage. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

• Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher amlodipine and atorvastatin dosage. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (Aripiprazol etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Asenapin etiketi, Uyarılar ve önlemler)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

(See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (Atenolol etiketi, Uyarılar)

Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (Atenolol ve klortalidon etiketi, Uyarılar)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (Atomoksetin etiketi, İlaç etkileşimleri)

• Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher amlodipine and atorvastatin dosage. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (Avanafil etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Amlodipine and atorvastatin tablets dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Drug Interactions that may Decrease Exposure to Atorvastatin Rifampin Clinical Impact: Concomitant administration of atorvastatin with rifampin, an inducer of cytochrome P450 3A4 and inhibitor of OATP1B1, can lead to variable reductions in plasma concentrations of atorvastatin. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

The thiazide component of Lotensin HCT may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. (Benazepril ve hidroklorotiyazid etiketi, Uyarılar)

Amphetamines may decrease the hypotensive effect of antihypertensives. (Benzfetamin etiketi, İlaç etkileşimleri)

HMG-CoA Reductase Inhibitors: lovastatin simvastatin ↑ lovastatin ↑ simvastatin Initiate lovastatin and simvastatin with the lowest starting dose and titrate carefully while monitoring for safety (e.g., myopathy). (Biktegravir, emtrisitabin ve tenofovir alafenamid etiketi, İlaç etkileşimleri)

Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Brekspiprazol etiketi, Uyarılar ve önlemler)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (Brimonidin etiketi, İlaç etkileşimleri)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (Bromfeniramin, psödoefedrin ve dekstrometorfan etiketi, İlaç etkileşimleri)

Use caution in patients taking antihypertensive medications. (Bromokriptin etiketi, Uyarılar ve önlemler)

Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with statins such as simvastatin, atorvastatin and lovastatin. (Danazol etiketi, İlaç etkileşimleri)

In patients who receive Daptomycin for Injection, CPK levels should be monitored weekly, and more frequently in patients who received recent prior or concomitant therapy with an HMG-CoA reductase inhibitor or in whom elevations in CPK occur during treatment with Daptomycin for Injection. (Daptomisin etiketi, Uyarılar ve önlemler)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Antihypertensive Drugs: Monitor blood pressure. (Deksmetilfenidat etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (Dietilpropion etiketi, İlaç etkileşimleri)

• Digoxin: May increase digoxin plasma levels; monitor patients appropriately ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of ZIPSOR with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (Diklofenak etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of diclofenac sodium/misoprostol with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.7) ] . (Diklofenak ve misoprostol etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (Dofetilid etiketi, İlaç etkileşimleri)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Dorzolamid ve timolol etiketi, İlaç etkileşimleri)

Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants. (Droperidol etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (Duloksetin etiketi, Uyarılar ve önlemler)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasterid etiketi, İlaç etkileşimleri)

Calcium Channel Antagonists Dutasteride Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasterid ve tamsulosin etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Amlodipine and atorvastatin tablets dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Concomitant use of TRIKAFTA may increase exposures of medicinal products that are substrates of these transporters, such as statins, glyburide, nateglinide and repaglinide. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Drug Interactions that may Decrease Exposure to Atorvastatin Rifampin Clinical Impact: Concomitant administration of atorvastatin with rifampin, an inducer of cytochrome P450 3A4 and inhibitor of OATP1B1, can lead to variable reductions in plasma concentrations of atorvastatin. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function. (Eplerenon etiketi, İlaç etkileşimleri)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Epoetin alfa etiketi, Uyarılar ve önlemler)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Epoprostenol etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

VYTORIN dosage modifications are recommended for patients taking lomitapide, verapamil, diltiazem, dronedarone, amiodarone, amlodipine or ranolazine [see Dosage and Administration (2.5) ] . (Ezetimib ve simvastatin etiketi, Uyarılar ve önlemler)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (Fenelzin etiketi, Uyarılar)

Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (Fenilefrin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (> 1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (> 1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Intervention: During concomitant use of FENOPROFEN CALCIUM with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (Fenoprofen etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Amlodipine and atorvastatin tablets dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Amlodipine and atorvastatin tablets dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Intervention: During concomitant use of flurbiprofen with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5) ]. (Flurbiprofen etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

The thiazide component of fosinopril sodium and hydrochlorothiazide may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. (Fosinopril ve hidroklorotiyazid etiketi, Uyarılar)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Monitor for changes in blood pressure and adjust the dose of other antihypertensive drugs if needed. (Furosemid etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

During concomitant use of hydrocodone bitartrate and ibuprofen tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (see WARNINGS: Renal Toxicity and Hyperkalemia ). (Hidrokodon ve ibuprofen etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of CALDOLOR with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (İbuprofen etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (İbuprofen ve famotidin etiketi, İlaç etkileşimleri)

In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (İkosapent etil etiketi, Uyarılar ve önlemler)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (İloperidon etiketi, Uyarılar ve önlemler)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Drug Interactions Other Antihypertensives: Indapamide may add to or potentiate the action of other antihypertensive drugs. (İndapamid etiketi, İlaç etkileşimleri)

Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 ) (İndometazin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Calcium Antagonists FORANE may lead to marked hypotension in patients treated with calcium antagonists. (İzofluran etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. (İzosorbid mononitrat etiketi, İlaç etkileşimleri)

Calcium Channel Blockers : Administration of calcium may reduce the response. (Kalsiyum glukonat etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (Karbidopa etiketi, İlaç etkileşimleri)

Antihypertensive drugs: May cause symptomatic postural hypotension. (Karbidopa ve levodopa etiketi, İlaç etkileşimleri)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (Karbidopa, levodopa ve entakapon etiketi, İlaç etkileşimleri)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Kariprazin etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ketiapin etiketi, Uyarılar ve önlemler)

The thiazide component of quinapril and hydrochlorothiazide tablets may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic- blocking drugs. (Kinapril ve hidroklorotiyazid etiketi, Uyarılar)

Atorvastatin (CYP3A4 Substrate) Rhabdomyolysis with acute renal failure secondary to myoglobinuria was reported in a patient taking atorvastatin administered with a single dose of quinine. (Kinin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Drugs that affect sinus node function or AV node conduction (e.g., digitalis, calcium channel blockers, beta blockers) Clinical Implication Concomitant use of drugs that affect sinus node function or AV node conduction with clonidine potentiate bradycardia and risk of AV block [see Warnings and Precautions (5.1) ]. (Klonidin etiketi, İlaç etkileşimleri)

Thiazides may add to or potentiate the action of other antihypertensive drugs. (Klorotiyazid etiketi, Uyarılar)

Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

Amlodipine and atorvastatin tablets dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (> 1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (Lakozamid etiketi, Uyarılar ve önlemler)

Examples of relevant classes of compounds where antacids have been demonstrated to reduce bioavailability include antibiotics (such as quinolones, ampicillin, and tetracyclines), thyroid hormones, ACE inhibitors, statin lipid regulators, and anti-malarials. (Lantan etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed (see DOSAGE AND ADMINISTRATION ). (Lisinopril ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (Lityum etiketi, İlaç etkileşimleri)

Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (Lomitapid etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin. (Lovastatin etiketi, İlaç etkileşimleri)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Lumateperon etiketi, Uyarılar ve önlemler)

Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (Lurasidon etiketi, Uyarılar ve önlemler)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of mefenamic acid with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.6 )] . (Mefenamik asit etiketi, İlaç etkileşimleri)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (Meflokin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (Mekamilamin etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of QAMZOVA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (Meloksikam etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Examples: Drugs known to have potential to prolong QT interval: Class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers. (Metadon etiketi, İlaç etkileşimleri)

Antihypertensive Drugs: Monitor blood pressure. (Metilfenidat etiketi, İlaç etkileşimleri)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Amlodipine and atorvastatin tablets dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (Mirtazapin etiketi, Uyarılar ve önlemler)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

( 5.3 Hepatotoxicity) Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Naproksen etiketi, Uyarılar ve önlemler)

Intervention : During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.6) ]. (Naproksen ve esomeprazol etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Non-dihydropyridine Calcium Channel Blockers Because of significant negative inotropic and chronotropic effects in patients treated with β-blockers and calcium channel blockers of the verapamil and diltiazem type, monitor the ECG and blood pressure in patients treated concomitantly with these agents. (Nebivolol etiketi, Uyarılar ve önlemler)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (> 1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (Nimodipin etiketi, İlaç etkileşimleri)

Antihypertensives: Possible additive hypotensive effects. (Nitrogliserin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of OXAPROZIN CAPSULES with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see WARNINGS AND PRECAUTIONS (5.6) ]. (Oksaprozin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Oktreotid etiketi, İlaç etkileşimleri)

…of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (Olanzapin etiketi, Uyarılar ve önlemler)

…and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

• Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher amlodipine and atorvastatin dosage. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (Paliperidon etiketi, Uyarılar ve önlemler)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Parasetamol ve ibuprofen etiketi, Uyarılar ve önlemler)

Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (Pasireotid etiketi, Uyarılar ve önlemler)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib etiketi, Uyarılar ve önlemler)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (Pentoksifilin etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Piroksikam etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (Prazosin etiketi, Uyarılar)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (> 1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

The concomitant use of beta-adrenergic blockers and non-dihydropyridine calcium channel blockers (e.g., verapamil and diltiazem), digoxin or clonidine increases the risk of significant bradycardia. (Propranolol etiketi, Uyarılar ve önlemler)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Rifampin: May reduce atorvastatin plasma concentrations. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (Riosiguat etiketi, Uyarılar ve önlemler)

Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (Risperidon etiketi, Uyarılar ve önlemler)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of VYSCOXA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5.6) ]. (Selekoksib etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (Sevofluran etiketi, İlaç etkileşimleri)

…concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (Siklobenzaprin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Sildenafil Monitor for hypotension when sildenafil is co-administered with amlodipine [see Clinical Pharmacology (12.2) ] . (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (Silodosin etiketi, Uyarılar ve önlemler)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

ZOCOR dosage modifications are recommended for patients taking lomitapide, verapamil, diltiazem, dronedarone, amiodarone, amlodipine or ranolazine [see Dosage and Administration (2.5) ] . (Simvastatin etiketi, Uyarılar ve önlemler)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

However, there was an increase in systemic exposure to weak acids such as furosemide and atorvastatin, and a decrease in systemic exposure to weak bases such as dabigatran when co-administered with LOKELMA, as shown in Figure 2. (Sodyum zirkonyum siklosilikat etiketi, İlaç etkileşimleri)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

Thiazides may add to or potentiate the action of other antihypertensive drugs. (Spironolakton ve hidroklorotiyazid etiketi, Uyarılar)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Sumatriptan ve naproksen etiketi, İlaç etkileşimleri)

Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib etiketi, Uyarılar ve önlemler)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended and adjust the dose when appropriate [see Clinical Pharmacology (12.3) ] . (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher amlodipine and atorvastatin dosage. (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (Temsirolimus etiketi, İlaç etkileşimleri)

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (Terazosin etiketi, Uyarılar ve önlemler)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (Testosteron etiketi, Uyarılar ve önlemler)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (Timolol etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (Trazodon etiketi, Uyarılar ve önlemler)

Thiazides may add to or potentiate the action of other antihypertensive drugs. (Triamteren ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (Vardenafil etiketi, İlaç etkileşimleri)

…ticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine,… (Varfarin etiketi, İlaç etkileşimleri)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Venlafaksin etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

Amlodipine and atorvastatin tablets dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2) ] . (Amlodipin ve atorvastatin etiketi, Uyarılar ve önlemler)

Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ziprasidon etiketi, Uyarılar ve önlemler)

Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (Adenozin etiketi, İlaç etkileşimleri)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (Beksaroten etiketi, Uyarılar ve önlemler)

In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (Butorfanol etiketi, Uyarılar)

Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (Dekstroamfetamin etiketi, İlaç etkileşimleri)

…malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants. [see Contraindications (4), Clinical Pharmacology (12.5)] Signs consistent with malignant hyperthermia may include hyperthermia, hypoxia,… (Desfluran etiketi, Uyarılar ve önlemler)

This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (Desipramin etiketi, Uyarılar)

Drug Interactions ACE-inhibitors and Angiotensin II Anagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (Diflunisal etiketi, İlaç etkileşimleri)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (Efedrin etiketi, İlaç etkileşimleri)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (Enalapril ve hidroklorotiyazid etiketi, Uyarılar)

Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Etodolak etiketi, İlaç etkileşimleri)

…acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant… (Finasterid etiketi, İlaç etkileşimleri)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (Fosinopril etiketi, Uyarılar)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Glibenklamid ve metformin etiketi, İlaç etkileşimleri)

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (Hidralazin etiketi, İlaç etkileşimleri)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (İkatibant etiketi, İlaç etkileşimleri)

In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (İsradipin etiketi, İlaç etkileşimleri)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (Kandesartan ve hidroklorotiyazid etiketi, Uyarılar)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (Kaptopril etiketi, Uyarılar)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. (Ketorolak etiketi, İlaç etkileşimleri)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (Kinapril etiketi, Uyarılar)

Interactions with other dihydropyridine calcium channel blockers have not been reported, but these agents (including felodipine, nicardipine, and nimodipine ) are all dependent upon P450 IIIA4 for metabolism, so similar interactions with quinidine should be anticipated. (Kinidin etiketi, İlaç etkileşimleri)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (Meksiletin etiketi, İlaç etkileşimleri)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Metformin etiketi, İlaç etkileşimleri)

Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

Because of its relative beta 1 cardio-selectivity, however, Metoprolol Tartrate Tablets may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Metoprolol etiketi, Uyarılar ve önlemler)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (Moeksipril etiketi, Uyarılar)

Drug Interactions: ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Nabumeton etiketi, İlaç etkileşimleri)

Should treatment with any HMG-CoA reductase inhibitor (a lipid lowering agent) be needed to treat lipid elevations, evaluate the potential for a drug-drug interaction before initiating therapy as certain HMG-CoA reductase inhibitors are metabolized by the CYP3A4 pathway [see Drug Interactions ( 7.1 )] . (Nilotinib etiketi, Uyarılar ve önlemler)

The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (Nisoldipin etiketi, İlaç etkileşimleri)

Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (Nitroprussid etiketi, Uyarılar)

The antihypertensive action of guanethidine and similar agents may be blocked. (Nortriptilin etiketi, Uyarılar)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Pioglitazon ve metformin etiketi, İlaç etkileşimleri)

Effient can be administered with aspirin (75 mg to 325 mg per day), heparin, GPIIb/IIIa inhibitors, statins, digoxin, and drugs that elevate gastric pH, including proton pump inhibitors and H 2 blockers [see Clinical Pharmacology (12.3) ] . (Prasugrel etiketi, İlaç etkileşimleri)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (Proklorperazin etiketi, Önlemler)

Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (Protriptilin etiketi, Uyarılar)

Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (Repaglinid etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Salsalat etiketi, İlaç etkileşimleri)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Sitagliptin ve metformin etiketi, İlaç etkileşimleri)

Drug Interactions ACE-Inhibitors and Angiotensin II Antagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (Sulindak etiketi, İlaç etkileşimleri)

QUELICIN can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants. [see Contraindications (4) , Clinical Pharmacology (12.5) ] . (Süksinilkolin etiketi, Uyarılar ve önlemler)

There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (Terbinafin etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. (Tolmetin etiketi, İlaç etkileşimleri)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (Trandolapril etiketi, Uyarılar)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (Trifluoperazin etiketi, Önlemler)

No other formal drug-drug interaction studies between zafirlukast and marketed drugs known to be metabolized by the P450 3A4 (CYP3A4) isoenzyme (e.g., dihydropyridine calcium-channel blockers, cyclosporin, cisapride) have been conducted. (Zafirlukast etiketi, Önlemler)

…clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3) ] . (Doravirin etiketi, İlaç etkileşimleri)

No clinically significant drug interactions have been observed between RPV and the following medications: acetaminophen, atorvastatin, chlorzoxazone, ethinyl estradiol, ledipasvir/sofosbuvir, norethindrone, sildenafil, simeprevir, sofosbuvir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, or TDF. (Emtrisitabin, rilpivirin ve tenofovir etiketi, İlaç etkileşimleri)

Calcium channel blocking agents: Coadministration of calcium channel blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials. (İbutilid etiketi, İlaç etkileşimleri)

Based on these data, ISENTRESS is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or P-glycoprotein (e.g., protease inhibitors, NNRTIs, opioid analgesics, statins, azole antifungals, proton pump inhibitors and anti-erectile dysfunction agents). (Raltegravir etiketi, İlaç etkileşimleri)

…included in Table 6, the interaction between EDURANT and the following drugs was evaluated in clinical studies and no dose adjustment is needed for either drug [see Clinical Pharmacology (12.3) ] : acetaminophen, atorvastatin, chlorzoxazone, cabotegravir, ethinylestradiol, norethindrone, raltegravir, sildenafil, simeprevir and tenofovir disoproxil fumarate. (Rilpivirin etiketi, İlaç etkileşimleri)